澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

AROVELLA THERAPEUTICS LTD

0.098

-0.001-1.01%

成交量：90.55萬

成交額：9.03萬

市值：1.18億

市盈率：-14.32

高：0.100

開：0.099

低：0.097

收：0.099

52周最高：0.195

52周最低：0.068

股本：12.01億

流通股本：8.96億

量比：0.80

換手率：0.10%

股息：- -

股息率：- -

每股收益(TTM):-0.007

每股收益(LYR):-0.007

淨資產收益率：-47.98%

總資產收益率：-28.30%

市淨率：5.86

市盈率(LYR):-14.32

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Arovella Therapeutics向美國FDA提交Ala-101首次人體一期試驗新藥研究申請

Arovella Therapeutics Ltd的CAR-iNKT細胞平台美國專利申請獲准授權

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ALA.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"ALA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ALA.AU\",,,,,undefined,":{"symbol":"ALA.AU","market":"AU","secType":"STK","nameCN":"AROVELLA THERAPEUTICS LTD","latestPrice":0.098,"timestamp":1770690710569,"preClose":0.099,"halted":0,"volume":905510,"delay":0,"changeRate":-0.010101010101010109,"nameEN":"AROVELLA THERAPEUTICS LTD","floatShares":895858885,"shares":1201183672,"eps":-0.006843,"marketStatus":"交易中","change":-0.001,"latestTime":"02-10 13:46:43 AEDT","open":0.099,"high":0.1,"low":0.097,"amount":90287,"amplitude":0.030303,"askPrice":0.098,"askSize":6375,"bidPrice":0.097,"bidSize":9400,"shortable":3,"etf":0,"ttmEps":-0.006843,"tradingStatus":2,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1770699600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.099,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":0.802239,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ALA.AU\",,,,,undefined,":{"symbol":"ALA.AU","floatShares":895858885,"roa":"-28.30%","roe":"-47.98%","lyrEps":-0.006843,"volumeRatio":0.802239,"shares":1201183672,"dividePrice":0,"high":0.1,"amplitude":0.030303,"preClose":0.099,"low":0.097,"week52Low":0.068,"pbRate":"5.86","psRate":"34.22","week52High":0.195,"institutionHeld":0,"latestPrice":0.098,"committee":0.191759,"eps":-0.006843,"divideRate":0,"volume":905510,"delay":0,"ttmEps":-0.006843,"open":0.099,"prevYearClose":0.093,"prevWeekClose":0.09,"prevMonthClose":0.086,"prevQuarterClose":0.093,"fiveDayClose":0.1,"twentyDayClose":0.094,"sixtyDayClose":0.096},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALA.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALA.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALA.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1138242283","title":"Arovella Therapeutics向美國FDA提交Ala-101首次人體一期試驗新藥研究申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1138242283","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138242283?lang=zh_tw&edition=fundamental","pubTime":"2025-12-30 09:19","pubTimestamp":1767057555,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics Ltd宣布已正式向美国食品药品监督管理局提交Ala-101的新药临床试验申请，该项申请旨在启动该药物的首次人体一期临床试验。这一重要进展标志着公司创新疗法开发迈入新的阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALA.AU","BK7096"],"gpt_icon":0},{"id":"1121490968","title":"Arovella Therapeutics Ltd的CAR-iNKT細胞平台美國專利申請獲准授權","url":"https://stock-news.laohu8.com/highlight/detail?id=1121490968","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121490968?lang=zh_tw&edition=fundamental","pubTime":"2025-08-28 06:29","pubTimestamp":1756333754,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics Ltd的CAR-iNKT细胞平台美国专利申请将获得授权批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALA.AU","BK7096"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ALA.AU\",params:#limit:6,delay:true,,,undefined,":[]}}